A U.S. District Court judge invalidated a Scale Biosciences (now part of 10x Genomics) patent asserted against Parse Biosciences, ruling the claims failed written description and enablement requirements. The decision concerns a split‑pool barcoding kit patent and follows earlier PTAB challenges that eroded related 10x/Scale patent claims. Parse announced the victory in its infringement litigation and emphasized the ruling’s implications for instrument‑free single‑cell library approaches. The opinion signals increased legal risk around broad single‑cell sequencing patents and may lower barriers for competing technologies that avoid specialized instruments.